医学
荟萃分析
急性胰腺炎
羟乙基淀粉
败血症
不利影响
内科学
临床试验
复苏
入射(几何)
随机对照试验
胃肠病学
胰腺炎
麻醉
物理
光学
作者
Marcello Di Martino,Stijn van Laarhoven,Benedetto Ielpo,José Manuel Ramia,Alba Manuel Vázquez,Aleix Martínez‐Pérez,Mihai Pavel,P Miranda,Rafael Orti‐Rodriguez,Sofía de la Serna,Guillermo J. Ortega,Ancor Sanz‐García,Elena Martín‐Pérez
出处
期刊:Hpb
[Elsevier]
日期:2021-07-08
卷期号:23 (11): 1629-1638
被引量:49
标识
DOI:10.1016/j.hpb.2021.06.426
摘要
Abstract Background Adequate fluid resuscitation is paramount in the management of acute pancreatitis (AP). The aim of this study is to assess benefits and harms of fluid therapy protocols in patients with AP. Methods MEDLINE, Embase, Science Citation Index and clinical trial registries were searched for randomised clinical trials published before May 2020, assessing types of fluids, routes and rates of administration. Results A total 15 trials (1073 participants) were included. Age ranged from 38 to 73 years; follow-up period ranged from 0.5 to 6 months. Ringer lactate (RL) showed a reduced number of severe adverse events (SAE) when compared to normal saline (NS) (OR 0.48; 95%CI 0.29–0.81, p = 0.006); additionally, NS showed reduced SAE (RR 0.38; 95%IC 0.27–0.54, p High fluid rate fluid infusion showed increased mortality (OR 2.88; 95%CI 1.41–5.88, p = 0.004), increased number of SAE (RR 1.42; 95%CI 1.04–1.93, p = 0.030) and higher incidence of sepsis (RR 2.80; 95%CI 1.51–5.19, p = 0.001) compared to moderate fluid rate infusion. Conclusions In patients with AP, RL should be preferred over NS and HES should not be recommended. Based on low-certainty evidence, moderate-rate fluid infusion should be preferred over high-rate infusion.
科研通智能强力驱动
Strongly Powered by AbleSci AI